DNA vaccines for cervical cancer: From bench to bedside

Experimental and Molecular Medicine

Volumn 39, Issue 6, 2007, Pages 679-689

  Hung, Chien Fu ^a   Monie, Archana ^a   Alvarez, Ronald D ^b   Wu, T C ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Antigen presenting cells; Dendritic cells; Human papillomavirus type 16; Oncogene protein E7; Papillomavirus vaccines; Vaccination; Vaccines, DNA

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENDRITIC CELL VACCINE; DNA VACCINE; EPIGALLOCATECHIN GALLATE; HEAT SHOCK PROTEIN 70; IMIQUIMOD; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROTEIN E6; PROTEIN E7; WART VIRUS VACCINE;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INTERACTION; CELL TRANSFORMATION; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DISEASE ASSOCIATION; DRUG ANTAGONISM; DRUG POTENCY; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE GUN; GENE GUN IMMUNIZATION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; NONHUMAN; REVIEW; T LYMPHOCYTE; UTERINE CERVIX CANCER;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; PAPILLOMAVIRIDAE;

EID: 38049174711     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.1038/emm.2007.74     Document Type: Review

References (68)

1. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B, Palucka K. Immunobiology of dendritic cells. Annual review of immunology 2000;18:767-811
2. Blank C, Mackensen A. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother 2007;56:739-45
3. Boursnell ME, Rutherford E, Hickling JK, Rollinson EA, Munro AJ, Rolley N, McLean CS, Borysiewicz LK, Vousden K, Inglis SC. Construction and characterisation of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer. Vaccine 1996;14:1485-94
4. + T cells: when, where, and how. Annual review of immunology 2006;24:519-40
5. Chen C-H, Wang T-L, Hung C-F, Yang Y, Young RA, Pardoll DM, Wu T-C. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Research 2000a;60:1035-42
6. Chen CH, Wang TL, Hung CF, Pardoll DM, Wu TC. Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines. Vaccine 2000b;18:2015-22
7. Cheng WF, Hung CF, Chai CY, Hsu KF, He L, Ling M, Wu TC. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest 2001;108:669-78
8. Condon C, Watkins SC, Celluzzi CM, Thompson K, Falo LD Jr. DNA-based immunization by in vivo transfection of dendritic cells. Nat Med 1996;2:1122-8
9. Cresswell P. Assembly, transport, and function of MHC class II molecules. Annual review of immunology 1994;12:259-93
10. Crook T, Morgenstern JP, Crawford L, Banks L. Continued expression of HPV-16 E7 protein is required for maintenance of the transformed phenotype of cells co-transformed by HPV-16 plus EJ-ras. Embo J 1989;8:513-9
11. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-9
12. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology 2004;324:17-27
13. Dilber MS, Phelan A, Aints A, Mohamed AJ, Elliott G, Smith CI, O'Hare P. Intercellular delivery of thymidine kinase prodrug activating enzyme by the herpes simplex virus protein, VP22. Gene Ther 1999;6:12-21
14. Donnelly JJ, Ulmer JB, Shiver JW, Liu MA. DNA vaccines. Annual review of immunology 1997;15:617-48
15. Dorange F, El Mehdaoui S, Pichon C, Coursaget P, Vautherot JF. Marek's disease virus (MDV) homologues of herpes simplex virus type 1 UL49 (VP22) and UL48 (VP16) genes: high-level expression and characterization of MDV-1 VP22 and VP16. J Gen Virol 2000;81 Pt 9:2219-30
16. Elliott G, O'Hare P. Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell 1997;88:223-33
17. Goldberg MV, Maris CH, Hipkiss EL, Flies AS, Zhen L, Tuder RM, Grosso JF, Harris TJ, Getnet D, Whartenby KA, Brockstedt DG, Dubensky TW Jr, Chen L, Pardoll DM, Drake CG. Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells. Blood 2007;110:186-92
18. Gorelik L, Flavell RA. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med 2001;7:1118-22
19. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002;419:734-8
20. Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. Annual Review of Immunology 2002;20:621-67
21. Gurunathan S, Klinman DM, Seder RA. DNA vaccines: immunology, application, and optimization. Annual Review of Immunology 2000;18:927-74
22. Harms JS, Ren X, Oliveira SC, Splitter GA. Distinctions between bovine herpesvirus 1 and herpes simplex virus type 1 VP22 tegument protein subcellular associations. J Virol 2000;74:3301-12
23. Hauser H, Chen SY. Augmentation of DNA vaccine potency through secretory heat shock protein-mediated antigen targeting. Methods 2003;31:225-31
24. Hauser H, Shen L, Gu QL, Krueger S, Chen SY. Secretory heat-shock protein as a dendritic cell-targeting molecule: a new strategy to enhance the potency of genetic vaccines. Gene Ther 2004;11:924-32
25. Huang CH, Peng S, He L, Tsai YC, Boyd DA, Hansen TH, Wu TC, Hung CF. Cancer immunotherapy using a DNA vaccine encoding a single-chain trimer of MHC class I linked to an HPV-16 E6 immunodominant CTL epitope. Gene Ther 2005;12:1180-6
26. Hung C-F, Cheng W-F, Chai C-Y, Hsu K-F, He L, Ling M, Wu T-C. Improving vaccine potency through intercellular spreading and enhanced MHC class I presentation of antigen. J Immunol 2001a;166:5733-40
27. Hung C-F, Cheng W-F, Hsu K-F, Chai C-Y, He L, Ling M, Wu T-C. Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen. Cancer Research 2001b;61:3698-703
28. Hung C-F, Hsu K-F, Cheng W-F, Chai CY, He L, Ling M, Wu T-C. Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Flt3-ligand. Cancer Research 2001c;61:1080-8
29. Hung CF, He L, Juang J, Lin TJ, Ling M, Wu TC. Improving DNA vaccine potency by linking Marek's disease virus type 1 VP22 to an antigen. J Virol 2002;76:2676-82
30. Hung CF, Cheng WF, He L, Ling M, Juang J, Lin CT, Wu TC. Enhancing major histocompatibility complex class I antigen presentation by targeting antigen to centrosomes. Cancer Res 2003;63:2393-8
31. Hung CF, Wu TC. Improving DNA vaccine potency via modification of professional antigen presenting cells. Curr Opin Mol Ther 2003;5:20-4
32. Hung C-F, Calizo R, Tsai YC, He L, Wu T-C. A DNA vaccine encoding a single-chain trimer of HLA-A2 linked to human mesothelin peptide generates anti-tumor effects against human mesothelin-expressing tumors. Vaccine 2007a;25:127-35
33. Hung CF, Tsai YC, He L, Wu TC. DNA vaccines encoding Ii-PADRE generates potent PADRE-specific CD4(+) T-cell immune responses and enhances vaccine potency. Mol Ther 2007b;15:1211-9
34. Ji H, Wang T-L, Chen C-H, Hung C-F, Pai S, Lin K-Y, Kurman RJ, Pardoll DM, Wu T-C. Targeting HPV-16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine HPV-16 E7-expressing tumors. Hum Gene Ther 1999;10:2727-40
35. Kang TH, Lee JH, Song CK, Han HD, Shin BC, Pai SI, Hung CF, Trimble C, Lim JS, Kim TW, Wu TC. Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination. Cancer Res 2007;67:802-11
36. Kim D, Hoory T, Wu T-C, Hung CF. Enhancing DNA Vaccine Potency by Combining a Strategy to Prolong Dendritic Cell Life and Intracellular Targeting Strategies with a Strategy to Boost CD4+ T cells. Human Gene Therapy 2007;18:1129-40
37. Kim JW, Hung CF, Juang J, He L, Kim TW, Armstrong DK, Pai SI, Chen PJ, Lin CT, Boyd DA, Wu TC. Comparison of HPV DNA vaccines employing intracellular targeting strategies. Gene Ther 2004a;11:1011-8
38. Kim TW, Hung CF, Ling M, Juang J, He L, Hardwick JM, Kumar S, Wu T-C. Enhancing DNA vaccine potency by co-administration of DNA encoding anti-apoptotic proteins. J Clin Invest 2003;112:109-17
39. Kim TW, Hung CF, Kim JW, Juang J, Chen PJ, He L, Boyd DA, Wu TC. Vaccination with a DNA vaccine encoding herpes simplex virus type 1 VP22 linked to antigen generates long-term antigen-specific CD8-positive memory T cells and protective immunity. Hum Gene Ther 2004b;15:167-77
40. Kim TW, Lee JH, He L, Boyd DA, Hardwick JM, Hung CF, Wu TC. Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency. Cancer Res 2005;65:309-16
41. Koptidesova D, Kopacek J, Zelnik V, Ross NL, Pastorekova S, Pastorek J. Identification and characterization of a cDNA clone derived from the Marek's disease tumour cell line RPL1 encoding a homologue of alpha-transinducing factor (VP16) of HSV-1. Arch Virol 1995;140:355-62
42. Lin CT, Tsai YC, He L, Calizo R, Chou HH, Chang TC, Soong YK, Hung CF, Lai CH. A DNA vaccine encoding a codon-optimized human papillomavirus type 16 E6 gene enhances CTL response and anti-tumor activity. J Biomed Sci 2006;13:481-8
43. Lundberg M, Johansson M. Is VP22 nuclear homing an artifact? Nat Biotechnol 2001;19:713-4
44. Munn DH, Mellor AL. IDO and tolerance to tumors. Trends Mol Med 2004;10:15-8
45. Mwangi W, Brown WC, Splitter GA, Zhuang Y, Kegerreis K, Palmer GH. Enhancement of antigen acquisition by dendritic cells and MHC class II-restricted epitope presentation to CD4+ T cells using VP22 DNA vaccine vectors that promote intercellular spreading following initial transfection. J Leukoc Biol 2005;78:401-11
46. Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L, Herber DL, Schneck J, Gabrilovich DI. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med 2007;13:828-35
47. Oliveira SC, Harms JS, Afonso RR, Splitter GA. A genetic immunization adjuvant system based on BVP22-antigen fusion. Hum Gene Ther 2001;12:1353-9
48. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108
49. Payne LG, Fuller DH, Haynes JR. Particle-mediated DNA vaccination of mice, monkeys and men: looking beyond the dogma. Curr Opin Mol Ther 2002;4:459-66
50. Peggs KS, Quezada SA, Korman AJ, Allison JP. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 2006;18:206-13
51. Peng S, Trimble C, Ji H, He L, Tsai YC, Macaes B, Hung CF, Wu TC. Characterization of HPV-16 E6 DNA vaccines employing intracellular targeting and intercellular spreading strategies. J Biomed Sci 2005;12:689-700
52. Perkins SD, Hartley MG, Lukaszewski RA, Phillpotts RJ, Stevenson FK, Bennett AM. VP22 enhances antibody responses from DNA vaccines but not by intercellular spread. Vaccine 2005;23:1931-40
53. Phelan A, Elliott G, O'Hare P. Intercellular delivery of functional p53 by the herpesvirus protein VP22. Nat Biotechnol 1998;16:440-3
54. Porgador A, Irvine KR, Iwasaki A, Barber BH, Restifo NP, Germain RN. Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization. J Exp Med 1998;188:1075-82
55. Roden R, Wu TC. How will HPV vaccines affect cervical cancer? Nat Rev Cancer 2006;6:753-63
56. Rubinstein N, Alvarez M, Zwirner NW, Toscano MA, Ilarregui JM, Bravo A, Mordoh J, Fainboim L, Podhajcer OL, Rabinovich GA. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell- mediated rejection; a potential mechanism of tumor-immune privilege. Cancer Cell 2004;5:241-51
57. Saha S, Yoshida S, Ohba K, Matsui K, Matsuda T, Takeshita F, Umeda K, Tamura Y, Okuda K, Klinman D, Xin KQ, Okuda K. A fused gene of nucleoprotein (NP) and herpes simplex virus genes (VP22) induces highly protective immunity against different subtypes of influenza virus. Virology 2006;354:48-57
58. Sciortino MT, Taddeo B, Poon AP, Mastino A, Roizman B. Of the three tegument proteins that package mRNA in herpes simplex virions, one (VP22) transports the mRNA to uninfected cells for expression prior to viral infection. Proc Natl Acad Sci USA 2002;99:8318-23
59. Stary G, Bangert C, Tauber M, Strohal R, Kopp T, Stingl G. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J Exp Med 2007;204:1441-51
60. Steinman RM. The dendritic cell system and its role in immunogenicity. Annual review of immunology 1991;9:271-96
61. Trimble C, Lin CT, Hung CF, Pai S, Juang J, He L, Gillison M, Pardoll D, Wu L, Wu TC. Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. Vaccine 2003;21:4036-42
62. Trombetta ES, Mellman I. Cell biology of antigen processing in vitro and in vivo. Annual review of immunology 2005;23:975-1028
63. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9
64. Wu T-C, Guarnieri FG, Staveley-O'Carroll KF, Viscidi RP, Levitsky HI, Hedrick L, Cho KR, August T, Pardoll DM. Engineering an intracellular pathway for MHC class II presentation of HPV-16 E7. Proc Natl Acad Sci 1995;92:11671-5
65. Wybranietz WA, Gross CD, Phelan A, O'Hare P, Spiegel M, Graepler F, Bitzer M, Stahler P, Gregor M, Lauer UM. Enhanced suicide gene effect by adenoviral transduction of a VP22-cytosine deaminase (CD) fusion gene. Gene Ther 2001;8:1654-64
66. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007;7:41-51
67. Yue FY, Dummer R, Geertsen R, Hofbauer G, Laine E, Manolio S, Burg G. Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. Int J Cancer 1997;71:630-7
68. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002;2:342-50